Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.3.1.900
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 9,589 $ 8,391
Marketable securities, current 39,091 50,209
Collaboration receivable 1,891 7,248
Prepaid expenses and other current assets 2,599 832
Total current assets 53,170 66,680
Property and equipment, net 333 557
Other assets 166 1,159
Total assets 53,669 68,396
Current liabilities:    
Accounts payable 725 2,074
Accrued clinical and development expenses 6,834 5,998
Accrued liabilities 3,269 3,180
Deferred revenue, current   14,722
Total current liabilities 10,828 25,974
Warrant liability 1,864 3,961
Deferred revenue, non-current   62,194
Deferred rent 131 243
Total liabilities $ 12,823 $ 92,372
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2015 and 2014; Issued and outstanding: 71,462,059 and 62,898,233 shares at December 31, 2015 and 2014, respectively. $ 71 $ 63
Additional paid-in capital 370,236 349,236
Accumulated other comprehensive loss (21) (13)
Accumulated deficit (329,440) (373,262)
Total stockholders’ equity (deficit) 40,846 (23,976)
Total liabilities and stockholders’ equity (deficit) $ 53,669 $ 68,396